Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
H.C. Wainwright5th Annual NASH Investor Conference Tuesday, October 12, 2021 3:30 pm Eastern Time H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference Wednesday, October 13, 2021 4:30 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Investor & Media Contacts:
Chief Financial Officer
Source: Altimmune, Inc